Operator: Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Third Quarter 2025 Earnings Conference Call.

The latest announcement is out from Takara Bio Inc. ( (JP:4974) ).

Takara Bio Inc. ( ($JP:4974) ) has shared an update. Takara Bio Inc. has revised its financial forecasts for the fiscal year ending March 31, ...

TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today ...

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announced the filing of its quarterly report on Form 10-Q for the quarter ended ...

SAN DIEGO and SUZHOU, China and SPRING HOUSE, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ('Adagene”) (Nasdaq: ADAG) ...

DALLAS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its ...

Q32 Bio Inc. (QTTB) on Thursday reported a loss of $7.4 million in its third quarter. The Waltham, Massachusetts-based company said it had a loss of ...

Partnership enables BIO-key technologies to be localized and delivered across Vietnam via SAVIS Group’s trusted services ...

Researchers have developed an ultra-mild bisulfite sequencing method (UMBS-seq) that preserves DNA integrity while delivering highly accurate methylation measurements. The new approach overcomes ...

Merck & Co. Inc. is buying Cidara Therapeutics Inc. for $9.2 billion to acquire a late-stage flu candidate and also to outrace blockbuster Keytruda’s looming patent expiration. CD-388, Cidara’s lead ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.